merck kgaa - Search News

News

Merck KGaA, SpringWorks

Reuters on MSN · 2d

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Bloomberg on MSN · 3d

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its health-care division. The purchase price of $47 per share in cash represents an equity value of about $3.

Seeking Alpha on MSN · 4d

Merck KGaA to buy Springworks for $3.9 billion

German healthcare and materials group Merck KGaA (OTCPK:MKGAF) to acquire U.S. biotech company SpringWorks Therapeutics (NASDAQ:SWTX) for an equity value of $3.9 billion to boost its cancer drug business,

Medical Marketing & Media18h

Rx Rundown: Merck KGaA, Novartis, Hims & Hers and more

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Merck's Bold $3.9 Billion Bid on SpringWorks: A Game-Changer in Rare Cancer Therapies

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

4d

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Merck agrees $3.9 billion takeover of SpringWorks

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results